MAGEC2 promotes tumorigenesis in multiple myeloma through USP16-mediated deubiquitination and stabilization of c-Myc
Zihao Liu, Tingting Hu, Jie Min, Chen Wang, Yuhao Cao, Mengjie Guo, Jinjun Qian, Chunyan Gu, Ye Yang · 2026
Read MAGEC2 promotes tumorigenesis in multiple myeloma through USP16-mediated deubiquitination and stabilization of c-Myc by Zihao Liu, Tingting Hu, Jie Min, Chen Wang, Yuhao Cao, Mengjie Guo, Jinjun Qian, Chunyan Gu, Ye Yang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13292446.txt.
Description
Zihao Liu and co-authors chase a 2026 target in multiple myeloma, starting from the toad-venom compound bufalin as a molecular fishing hook. Proteomics pulled out MAGEC2 as a direct binding partner. Checking patient cohorts, the team found high MAGEC2 matched poor overall survival in this incurable plasma cell cancer.
In cells and a mouse transfer model, MAGEC2 pushed malignant growth and blunted two standard drugs, adriamycin and bortezomib. Beyond its known habit of boosting E3 ligases, it grabbed the deubiquitinase USP16 and cranked up its activity, which stabilized the growth driver c-Myc by trimming its ubiquitin tags. Extra MAGEC2 also worsened bone lesions in animals. The authors nominate MAGEC2 as both a warning marker and a drug target.
Catalog record
| CREATOR | Zihao Liu, Tingting Hu, Jie Min, Chen Wang, Yuhao Cao, Mengjie Guo, Jinjun Qian, Chunyan Gu, Ye Yang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17694 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |